EC approves Sprycel for first-line CML

The EC approved an MAA to extend the indication of Sprycel dasatinib from Bristol-Myers Squibb Co. (NYSE:BMY) to include first-line treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) ...